Rapid Whole-Genome Sequencing for Genetic Disease Diagnosis in Neonatal Intensive Care Units

Center for Pediatric Genomic Medicine, Children's Mercy Hospital, Kansas City, MO 64108, USA.
Science translational medicine (Impact Factor: 15.84). 10/2012; 4(154):154ra135. DOI: 10.1126/scitranslmed.3004041
Source: PubMed


Monogenic diseases are frequent causes of neonatal morbidity and mortality, and disease presentations are often undifferentiated at birth. More than 3500 monogenic diseases have been characterized, but clinical testing is available for only some of them and many feature clinical and genetic heterogeneity. Hence, an immense unmet need exists for improved molecular diagnosis in infants. Because disease progression is extremely rapid, albeit heterogeneous, in newborns, molecular diagnoses must occur quickly to be relevant for clinical decision-making. We describe 50-hour differential diagnosis of genetic disorders by whole-genome sequencing (WGS) that features automated bioinformatic analysis and is intended to be a prototype for use in neonatal intensive care units. Retrospective 50-hour WGS identified known molecular diagnoses in two children. Prospective WGS disclosed potential molecular diagnosis of a severe GJB2-related skin disease in one neonate; BRAT1-related lethal neonatal rigidity and multifocal seizure syndrome in another infant; identified BCL9L as a novel, recessive visceral heterotaxy gene (HTX6) in a pedigree; and ruled out known candidate genes in one infant. Sequencing of parents or affected siblings expedited the identification of disease genes in prospective cases. Thus, rapid WGS can potentially broaden and foreshorten differential diagnosis, resulting in fewer empirical treatments and faster progression to genetic and prognostic counseling.

Download full-text


Available from: Stephen F Kingsmore, Jan 04, 2014

Click to see the full-text of:

Article: Rapid Whole-Genome Sequencing for Genetic Disease Diagnosis in Neonatal Intensive Care Units

1.3 MB

See full-text
  • Source
    • "In recent years, high throughput sequencing has generated thousands of new genomes from various species across the tree of life and millions of genetic variants. Especially in the field of human genetics, targeted or whole exome and genome sequencing are becoming standard assays (Ng et al., 2010; Ng et al., 2009; Saunders et al., 2012) to identify causal single-nucleotide variations (SNVs) as well as short insertions/deletions (indels) "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Most genetic disorders are caused by single nucleotide variations (SNVs) or small insertion/deletions (indels). High throughput sequencing has broadened the catalogue of human variation, including common polymorphisms, rare variations or disease causing mutations. However, identifying one variation among hundreds or thousands of others is still a complex task for biologists, geneticists and clinicians. Results. We have developed VaRank, a command-line tool for the ranking of genetic variants detected by high-throughput sequencing. VaRank scores and prioritizes variants annotated either by Alamut Batch or SnpEff. A barcode allows users to quickly view the presence/absence of variants (with homozygote/heterozygote status) in analyzed samples. VaRank supports the commonly used VCF input format for variants analysis thus allowing it to be easily integrated into NGS bioinformatics analysis pipelines. VaRank has been successfully applied to disease-gene identification as well as to molecular diagnostics setup for several hundred patients. Conclusions. VaRank is implemented in Tcl/Tk, a scripting language which is platform-independent but has been tested only on Unix environment. The source code is available under the GNU GPL, and together with sample data and detailed documentation can be downloaded from http://www.lbgi.fr/VaRank/.
    PeerJ 03/2015; 3(3):e796. DOI:10.7717/peerj.796 · 2.11 Impact Factor
  • Source
    • "WGS, and whole-exome sequencing, have already been used to provide genetic diagnoses that inform clinical care (Worthey et al., 2011; Bainbridge et al., 2011; Rios et al., 2010). These early successes in individual patients prompted expanded studies to investigate a more general use of WGS in clinical settings (Saunders et al., 2012). Indeed the growing adoption of WGS in the clinic and the potential to positively impact patient care contributed, at least in part, to the UK100K Project, an effort by the Department of Health (United Kingdom) to provide highcoverage WGS for clinical interpretation in 100,000 participants focusing initially on rare diseases, cancer and infectious disease (www. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical value of WGS in the cancer genetics clinic is unknown. We performed WGS on members of two cohorts of cancer genetics patients: those with BRCA1/2 mutations (n = 176) and those without (n = 82). Initial analysis of potentially pathogenic variants (PPVs, defined as nonsynonymous variants with allele frequency < 1% in ESP6500) in 163 clinically-relevant genes suggested that WGS will provide useful clinical results. This is despite the fact that a majority of PPVs were novel missense variants likely to be classified as variants of unknown significance (VUS). Furthermore, previously reported pathogenic missense variants did not always associate with their predicted diseases in our patients. This suggests that the clinical use of WGS will require large-scale efforts to consolidate WGS and patient data to improve accuracy of interpretation of rare variants. While loss-of-function (LoF) variants represented only a small fraction of PPVs, WGS identified additional cancer risk LoF PPVs in patients with known BRCA1/2 mutations and led to cancer risk diagnoses in 21% of non-BRCA cancer genetics patients after expanding our analysis to 3209 ClinVar genes. These data illustrate how WGS can be used to improve our ability to discover patients' cancer genetic risks.
    01/2015; 371(1). DOI:10.1016/j.ebiom.2014.12.003
  • Source
    • "The International Rare Disease Research Consortium (IRDiRC) has been established to bring together researchers and organizations investing in rare disease research in order to achieve two main objectives by the year 2020, namely to deliver 200 new therapies for rare diseases and the means to diagnose most rare diseases (http://www.irdirc.org). In future, it may be feasible to examine the natural history of disease in each patient, and look for changes in the 'slope' following treatment in n= 1 trials [51] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rare Disease registries have now been recognized as a global priority for progress in monitoring, documenting the natural course, preventing and treating Rare Diseases. However, a disease registry is only one element of Rare Disease translational research. Here, we outline what we believe are ten key components in comprehensive Rare Disease translational research and describe critical relationships between them. These components are: i) Client-practitioner partnerships; ii) Disease registries; iii) Biobanks; iv) Genomics and other -omics platforms; v) Community-based and population-wide studies; vi) Bioinformatics and high performance computing; vii) Interactions with pharma to facilitate drug discovery; viii) Personalised treatments based on genotype-phenotype correlations; ix) eHealth and a whole of life record; and x) Regulatory frameworks, particularly with regard to specimen and data sharing, and return of results. Each component has its own inherent complexity, but if effectively integrated they will provide for a comprehensive approach to the future management of Rare Diseases, and aid health care providers in delivering services for individuals affected with Rare Diseases. We demonstrate that navigating through the Roadmap can provide relevant health stakeholders with a blueprint to understand the challenges and barriers which need to be overcome within and across the constituent components. The Rare Disease Roadmap will assist decision-making at all health stakeholder levels and enable the seamless integration of new knowledge, standard operating procedures and the implementation of best practice.
    Health Policy and Technology 08/2014; 3(4). DOI:10.1016/j.hlpt.2014.08.007
Show more